Cadrenal Therapeutics, Inc. Common Stock (CVKD)

Cadrenal Therapeutics, Inc. Common Stock (CVKD) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $4.1M; returns 1 day -1.0%, 1 week -11.9%, 1 year -93.0%.

Cadrenal Therapeutics, Inc. (CVKD) is a late-stage biopharmaceutical company focused on developing therapeutics for rare cardiovascular conditions. Their lead product candidate is Tecarfarin, a novel oral Vitamin K antagonist anticoagulant designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.

Groups CVKD belongs to

• Biotechnology
• Biopharmaceutical
• Cardiovascular Therapies
• Clinical Stage
• Clinical Stage Biopharma
• Rare Diseases
• Healthcare
• Life Sciences

CVKD financial model: income statement, cash flow and balance sheet